![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC38A11 |
Gene summary for SLC38A11 |
![]() |
Gene information | Species | Human | Gene symbol | SLC38A11 | Gene ID | 151258 |
Gene name | solute carrier family 38 member 11 | |
Gene Alias | AVT2 | |
Cytomap | 2q24.3 | |
Gene Type | protein-coding | GO ID | GO:0003333 | UniProtAcc | Q08AI6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
151258 | SLC38A11 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.96e-35 | 7.12e-01 | 0.3005 |
151258 | SLC38A11 | CRC-1-8810 | Human | Colorectum | CRC | 1.40e-59 | 1.18e+00 | 0.6257 |
151258 | SLC38A11 | HCC1_Meng | Human | Liver | HCC | 1.68e-03 | -1.05e-01 | 0.0246 |
151258 | SLC38A11 | HCC2 | Human | Liver | HCC | 9.53e-11 | 1.23e-01 | 0.5341 |
151258 | SLC38A11 | S014 | Human | Liver | HCC | 6.29e-04 | 5.45e-01 | 0.2254 |
151258 | SLC38A11 | S016 | Human | Liver | HCC | 5.14e-12 | 6.80e-01 | 0.2243 |
151258 | SLC38A11 | HTA12-23-1 | Human | Pancreas | PDAC | 8.00e-12 | 8.81e-01 | 0.3405 |
151258 | SLC38A11 | HTA12-25-1 | Human | Pancreas | PDAC | 3.52e-06 | 5.06e-01 | 0.313 |
151258 | SLC38A11 | HTA12-26-1 | Human | Pancreas | PDAC | 4.88e-07 | 4.28e-01 | 0.3728 |
151258 | SLC38A11 | HTA12-29-1 | Human | Pancreas | PDAC | 6.38e-18 | 5.05e-01 | 0.3722 |
151258 | SLC38A11 | HTA12-32-1 | Human | Pancreas | PDAC | 1.46e-03 | 8.99e-01 | 0.3624 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00068141 | Colorectum | CRC | sodium ion transport | 49/2078 | 245/18723 | 3.01e-05 | 7.86e-04 | 49 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC38A11 | SNV | Missense_Mutation | c.143N>A | p.Gly48Asp | p.G48D | Q08AI6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-L9-A443-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC38A11 | SNV | Missense_Mutation | c.151G>T | p.Gly51Trp | p.G51W | Q08AI6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-22-5478-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SLC38A11 | SNV | Missense_Mutation | novel | c.271G>C | p.Glu91Gln | p.E91Q | Q08AI6 | protein_coding | tolerated(0.18) | benign(0.009) | TCGA-BA-A4IG-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | erbitux | CR |
SLC38A11 | SNV | Missense_Mutation | novel | c.769C>A | p.Pro257Thr | p.P257T | Q08AI6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CR-7399-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC38A11 | SNV | Missense_Mutation | novel | c.340T>G | p.Leu114Val | p.L114V | Q08AI6 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-CV-5432-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
SLC38A11 | SNV | Missense_Mutation | c.613N>A | p.Val205Met | p.V205M | Q08AI6 | protein_coding | tolerated(0.26) | benign(0.042) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD | |
SLC38A11 | SNV | Missense_Mutation | c.514N>C | p.Ser172Pro | p.S172P | Q08AI6 | protein_coding | deleterious(0.01) | probably_damaging(0.968) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
SLC38A11 | SNV | Missense_Mutation | c.295N>G | p.Phe99Val | p.F99V | Q08AI6 | protein_coding | tolerated(0.19) | benign(0.038) | TCGA-CD-5801-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
SLC38A11 | SNV | Missense_Mutation | novel | c.820N>T | p.Gly274Trp | p.G274W | Q08AI6 | protein_coding | deleterious(0.01) | probably_damaging(0.926) | TCGA-ET-A25R-01 | Thyroid | thyroid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |